Fractyl Health, Inc. (NASDAQ:GUTS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Fractyl Health, Inc. (NASDAQ:GUTS) have received an average rating of “Moderate Buy” from the five ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $7.40.

A number of equities analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a report on Tuesday, December 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fractyl Health in a research report on Monday, December 29th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Friday, December 19th.

Fractyl Health Stock Down 3.0%

NASDAQ GUTS opened at $1.91 on Friday. Fractyl Health has a fifty-two week low of $0.83 and a fifty-two week high of $3.03. The business has a 50 day moving average price of $1.89 and a two-hundred day moving average price of $1.51. The stock has a market cap of $261.75 million, a PE ratio of -0.83 and a beta of 1.62.

Fractyl Health (NASDAQ:GUTS) last released its earnings results on Wednesday, November 12th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Sell-side analysts anticipate that Fractyl Health will post -1.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Fractyl Health

A number of institutional investors have recently modified their holdings of GUTS. FNY Investment Advisers LLC boosted its position in Fractyl Health by 143.3% during the fourth quarter. FNY Investment Advisers LLC now owns 48,650 shares of the company’s stock worth $107,000 after purchasing an additional 28,650 shares during the period. JPMorgan Chase & Co. bought a new position in shares of Fractyl Health in the third quarter valued at approximately $81,000. Woodline Partners LP lifted its stake in shares of Fractyl Health by 821.1% in the third quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock worth $8,755,000 after buying an additional 4,908,693 shares during the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of Fractyl Health during the 3rd quarter worth $8,981,000. Finally, Scientech Research LLC bought a new stake in shares of Fractyl Health during the 3rd quarter worth $49,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.